TRIP13 and cancer: TRIP13 was first reported as an oncogene of head and neck cancer in 2014 [30], then other subsequent studies on cancers identified that TRIP13 might have oncogenic effects by promoting tumor cell proliferation, invasion, and metastasis [31–33].